

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following drug types best describes the mechanism of action of the novel agent nirogacestat?
 - NTRK inhibitor
 - Gamma-secretase inhibitor
 - Tyrosine kinase inhibitor
 - mTOR inhibitor
- In clinical trials regorafenib has demonstrated activity and improved progression-free survival (PFS) in all histologic subtypes of soft tissue sarcoma EXCEPT which one?
 - Leiomyosarcoma
 - Extraskeletal osteosarcoma
 - Synovial sarcoma
 - Liposarcoma
- The majority of patients with gastrointestinal stromal tumors (GIST) have a mutation in which of the following genes?
 - KIT
 - NTRK
 - BRAF
 - NF1
- Which of the following results was reported from the INVICTUS study comparing ripretinib to placebo as fourth- or later-line therapy for patients with advanced GIST?
 - Median PFS was improved, but median overall survival (OS) was not
 - Median OS was improved, but median PFS was not
 - Neither median PFS nor median OS was improved
 - Both median PFS and median OS were improved
- Tazemetostat acts by inhibiting which of the following targets?
 - CDK4/6
 - EZH2
 - PDGFR
 - mTOR